Shionogi & Co (TYO:4507) said 89% of HIV patients in a ViiV Healthcare study opted to switch from daily pills to long-acting injectable Cabenuva, according to a Thursday filing on the Tokyo Stock Exchange.
The Phase IIIb VOLITION trial, presented at the IAS 2025 conference, involved treatment-naïve adults who achieved rapid viral suppression with oral Dovato.
Most chose to switch to Cabenuva, citing convenience and reduced anxiety about missing doses.
ViiV is jointly owned by Shionogi, GlaxoSmithKline and Pfizer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.